Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome
C Janko, S André, LE Munoz, JP Briand, C Schorn, S Winkler, M Schiller, L Andreoli, AA Manfredi, DA Isenberg, G Schett, HJ Gabius, S Muller and M Herrmann
Lupus 2012 21: 781
DOI: 10.1177/0961203312443422

The online version of this article can be found at:
http://lup.sagepub.com/content/21/7/781

Published by:
SAGE
http://www.sagepublications.com

Additional services and information for Lupus can be found at:

Email Alerts: http://lup.sagepub.com/cgi/alerts
Subscriptions: http://lup.sagepub.com/subscriptions
Reprints: http://www.sagepub.com/journalsReprints.nav
Permissions: http://www.sagepub.com/journalsPermissions.nav

>> Version of Record - May 25, 2012
What is This?
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome

C Janko 1,*, S André 2,*, LE Munoz 1, JP Briand 3, C Schorn 1, S Winkler 3, M Schiller 4, L Andreoli 5, AA Manfredi 6, DA Isenberg 7, G Schett 1, HJ Gabius 2,#, S Muller 3,# and M Herrmann 1,#

1Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany; 2Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University Munich, Munich, Germany; 3Centre National de la Recherche Scientifique, Institut de Biologie Moleculaire et Cellulaire, Strasbourg, France; 4Department of Medicine V, University of Heidelberg, Heidelberg, Germany; 5Rheumatology and Clinical Immunology, Spedali Civili, University of Brescia, Brescia, Italy; 6Hospital San Raffaele Scientific Institute and University Vita-Salute San Raffaele, Milano, Italy; and 7Department of Medicine, Centre for Rheumatology, University College London, London, UK

Autoantibodies against opsonins of dying and dead cells mediate Fcγ receptor-dependent phagocytosis of autologous apoptotic and necrotic cells and hereby tend to elicit inflammation instead of silent clearance. We analysed sera of patients with chronic autoimmune diseases for the occurrence of IgG autoantibodies recognizing galectins. These pluripotent effectors can also bind to apoptotic or necrotic cells. Patients with antiphospholipid syndrome (APS; n = 104) and systemic lupus erythematosus (SLE; n = 62) were examined, healthy donors (n = 31) served as controls. Selected peptides of galectin (Gal)-2 were employed for peptide-based ELISAs. Levels of anti-Gal-2 PEP-IgG were significantly increased in SLE and APS when compared with controls. In addition, patients with APS showed significantly higher levels of anti-Gal-2 PEP-IgG compared with patients with SLE. Anti-Gal-2 PEP-IgG may, therefore, be considered novel biomarkers for APS. Lupus (2012) 21, 781–783.

Key words: antiphospholipid syndrome; autoantibodies; lectins; systemic lupus erythematosus

Introduction

A fast and effective clearance of dying and dead cells is essential to prevent secondary necrosis, accompanied by leakage of autoantigens and inflammation. Compounds from uncleared cells have been discussed to elicit production of autoantibodies in chronic inflammatory diseases. To ensure silent clearance of apoptotic cells, a plethora of soluble adaptor molecules assists in bridging dying cells to phagocytes. Galectins (Gal), a family of endogenous lectins sharing galactoside specificity and sequence signature/folding, bind apoptotic and necrotic cells and an involvement in clearance for Gal-3 is suggested. For interest, opsonins (e.g. Gal) can often become targets of an adaptive humoral immune response followed by autoimmune disease. To address this issue for Gal we analysed anti-Gal-IgG in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) employing peptide-based ELISAs.

Patients and methods

Sera were processed from 104 patients with primary or secondary APS, 62 patients with SLE, and 31 healthy blood donors (HBDs) who served as controls. Patients were diagnosed as APS according the revised classification criteria for APS. Patients classified as SLE met the classification criteria of the American College of Rheumatology for SLE. Clinical manifestations and serological parameters of the patients are compiled in Table 1. Three chemically synthesized Gal-2 derived
peptides, namely a N-terminal 19mer (M1-K19), a central 18mer (C57-L74) and a C-terminal 21mer (S112-E132) were tested. The full-size Gal-2 was obtained by recombinant production and purified by affinity chromatography. Anti-Gal-2 IgG in sera of autoimmune patients were detected by ELISAs. The cut-off level was defined as the 99th percentile of the optical density (OD) values of HBD. Experimental values are expressed as mean OD of the duplicates of each serum. SPSS 17.0 software was used for statistic calculations.

**Results and discussion**

We compared the reactivity of IgG autoantibodies against the three Gal-2 peptides in sera of patients with SLE and APS with the reactivity against the recombinant protein. A significant correlation (Spearman) of the peptide reactivity with that of the corresponding full-size protein was obtained (Figure 1). Compared with HBD controls significantly increased IgG-antibody levels against Gal-2PEP were found in patients with APS and SLE (Figure 2). Interestingly, the anti-Gal-2 PEP IgG in the APS cohort was significantly increased compared with HBD controls.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number of patients</th>
<th>sex (% female)</th>
<th>age (years; mean ± standard deviation)</th>
<th>thrombotic event &amp; pulmonary embolism</th>
<th>obstetric complications</th>
<th>cerebral vascular event</th>
<th>Raynaud-Syndrome</th>
<th>Lupus anti-coagulant (IgG or IgM)</th>
<th>anti-CL (IgG or IgM)</th>
<th>anti-β2GP1 (IgG or IgM)</th>
<th>category I: (more than one laboratory criteria present)</th>
</tr>
</thead>
<tbody>
<tr>
<td>APS</td>
<td>104</td>
<td>80.8</td>
<td>46.0 ± 12.0</td>
<td>59</td>
<td>32</td>
<td>13</td>
<td>13</td>
<td>56</td>
<td>72</td>
<td>47</td>
<td>49</td>
</tr>
<tr>
<td>SLE</td>
<td>62</td>
<td>83.9</td>
<td>40.4 ± 14.3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>15</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

APS patients met the revised classification criteria for APS. SLE patients met the classification criteria of the American College of Rheumatology for SLE.

**Table 1** Clinical manifestations and serological parameters of the patients

**Figure 1** Autoantibodies against Gal-2 and the corresponding Gal-2-derived peptides correlate in sera of patients with SLE and APS. R and p-values of the Spearman-rho correlations are indicated. The cut-off levels (99th percentile of the HBD) were inserted as boxes into the graphs. Amino acid sequences are shown in http://www.ncbi.nlm.nih.gov/protein/NP_006489.1. The sequences of the Gal-2 peptides are: MTGELEVKNMDMKPGSTLK (M1-K19), CNSLDGSNWGQEQREDHL (C57-L74), and SHLSYLSVR GGFNMSSFKLKE (S112-E132).

**Figure 2** Patients with APS and SLE show increased levels of anti-Gal-2PEP-IgG. Anti-Gal-2PEP-IgG were measured by ELISA, displayed are the mean values of the three anti-Gal-2PEP-IgG. The 99th percentile of the HBD was set as cut-off value (open circles <99th; closed circles >99th percentile of the HBD). Indicated are the percentages of the patients with Gal-2PEP-IgG > cut-off value. The horizontal bar represents the median values of one cohort. HBD, healthy blood donor; SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome. Significances were calculated by Mann–Whitney U tests. **p < 0.01.
when compared with the SLE cohort containing no patients with APS. Anti-Gal-2\textsuperscript{PEP}-IgG may, therefore, be considered as novel biomarkers for APS.

**Funding**

This work was supported by the Masterswitch project of the EU, the DFG (training grant SFB 643), the Interdisciplinary Center of Clinical Research (IZKF, grant number TP A41) at the University Hospital of the University of Erlangen-Nuremberg, the K&R Wucherpfennig Stiftung, the EC (GlycoHIT, grant number 260600), and CNRS (to JPB and SM).

**Conflict of interest**

The authors declare no conflict of interest.

**References**